Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) CEO Shares Insights on the Psychedelics Space on The Dealmaker Podcast

  • Mr. Greg McKee, CEO of Tryp Therapeutics, appeared on The Dealmaker Podcast to share insights on the company and the psychedelics industry
  • During the interview, he discussed the potential of psychedelics in the treatment of PTSD and other mental disorders
  • Greg also shared the challenges that the industry is facing currently, mostly to do with legislation
  • McKee also shared how people can help the company and the industry by pushing for the decriminalization of psychedelics and taking part in clinical trials

On August 2, 2021, the Dealmaker Podcast posted an interview with Greg McKee, the Chief Executive Officer (“CEO”) of Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF). The show, hosted by Oren Klaff, sought to give the audience an understanding of Tryp Therapeutics’ operations, along with Mr. McKee’s personal story on how he ended up as the CEO of the company ( It offered some great insights into the future of the psychedelics space, along with what ordinary people can do to take the industry to the next level.

When discussing what Tryp Therapeutics is all about, Mr. McKee acknowledged the current boom in the psychedelics space and the potential that these substances hold. He noted:

“There are a lot of naturally-derived chemistries around that eventually find their way into more traditional drug development pathways. Psychedelics are some of those.” 

Mr. McKee mentioned his interaction with former Navy SEALs, all of whom developed Post-Traumatic Stress Disorder (“PTSD”), along with other mental disorders. The patients did not see lasting efficacy on their current and standard of care treatments. Their use of more mainstream forms of therapy and treatment did not seem to work until they tried 5-MeO-DMT, a psychedelic. However, these patients did see an impact after using a psychedelic compound.

The success of this psychedelic to these former Navy SEALs gave McKee the reassurance he needed that psychedelics could be of help, not just to former military officers but also to millions of other patients who suffer from chronic pain. However, he noted the most important hindrance along the way, approval.

“If we can bring these chemistries to market through an FDA pathway, then we think we can completely change those patients’ lives, along with many, many other kinds of patients that suffer from chronic pain,” he noted (

Tryp Therapeutics is a pharmaceutical company that develops clinical-stage compounds designed to treat diseases with high unmet medical needs. It seeks to achieve this through accelerated regulatory pathways. The company’s current flagship program involves developing synthetic psilocybin drug candidates to treat chronic pain and eating disorder indications. It regards itself as a pioneer in developing psilocybin-related drugs and hopes to follow the same path as some cannabis pioneers that have made waves and achieved a lot in the past couple of years.

The interview showed Mr. McKee’s passion for the job and how much he aligns with his company’s vision. He pointed out that although he is not the founder of the company, he understood the vision that the founder had for the company and the commitment it takes to be the company’s CEO.

More importantly, Mr. McKee cited the benefits that come with the use of psilocybin in treating pain. For one, he discussed their effectiveness without the accompanying risk of addiction associated with opioids. He also acknowledged that psychedelics are far from mainstream, but that is an opportunity for the company to play the role of a first-mover.

“They (psychedelics) are not mainstream yet. That’s actually the opportunity. Nobody’s done that yet. We’re just now making them synthetically and making them up to pharmaceutical-grade standards,” Mr. McKee noted.

McKee noted that FDA approvals take time. However, he pointed out that if anyone wanted to play a role in the industry’s growth and, more specifically, the development of Tryp Therapeutics, they could write to or call their legislators to push for the decriminalization of psychedelics. He also noted that the company welcomes people with any diseases it addresses to participate in their clinical study.

This interview offered a glimpse into Tryp Therapeutics operations, the opportunities and challenges within the psychedelics industry. Additionally, it provided insights into Mr. McKee’s ambitions, his vision for the company, along with his informed opinion on the psychedelics industry that is currently experiencing a spike in growth.

To listen to the whole podcast episode, please visit

For more information, visit the company’s website at

NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at 

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published:

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
415.949.5050 Office

PsychedelicNewsWire is part of the InvestorBrandNetwork.


Select A Month

PsychedelicNewsWire Currently Accepts



Bitcoin Cash

Bitcoin Cash

Doge Coin






USD Coin

USD Coin

Contact us: 415.949.5050